免疫療法薬の世界市場レポート 2024年

免疫療法薬の市場規模は、今後数年間で急速に成長すると予想されます。 2028年には12.1%の年間複合成長率（CAGR）で4,451億2,000万米ドルに成長すると予想されます。予測期間中に予想される成長は、併用療法の導入、個別化医療の台頭、世界的な拡大への取り組み、バイオマーカー主導の治療法の開発、臨床試験の拡大によってもたらされると予想されます。この期間に予測される主要な動向には、免疫学の進歩、CAR-T細胞療法の進歩、標的免疫療法の出現、免疫療法の組み合わせの探求、ネオアンチゲンワクチンを取り巻く技術革新が含まれます。

世界中でがんの有病率が急増していることが、免疫療法市場における医薬品の需要の高まりの主要原動力となっています。肥満、喫煙、飲酒、食習慣などの要因により、がん症例の増加は大幅に増加すると予測されています。 2022年10月のMacmillan Cancer Supportの報告書では、がん症例の急増が推定され、2025年までに350万人、2030年までに400万人、2040年までに530万人になると予測されています。乳がん、肺がん、結腸がん、直腸がん、と前立腺がんが最も蔓延しているがんとしてランク付けされています。がんによる死亡の約3分の1には、種類、喫煙などのライフスタイル要素、高いBMI、果物と野菜の摂取制限、アルコール摂取、運動不足が寄与しています。このがん罹患率の上昇により、免疫療法薬の需要が高まり、その結果、市場の成長が促進されると考えられます。

医療費の増加軌道は、免疫療法薬市場の成長を推進する原動力として機能すると予想されます。医療支出には、指定された期間にわたる特定の地域または国の医療サービスに対する集合的な金銭支出が含まれ、診察、入院、外科的処置、診断、治療にかかる費用が含まれます。特に、2023年5月にOffice for National Statisticsが発表した最近の統計では、英国内の医療費の大幅な急増が示されています。統計によると、名目9.4%増、実質9.7%増で、2021年の医療支出総額は3,672億5,000万米ドル（2,807億ポンド）に達しました。特に医薬品への支出は518億4,000万米ドル（396億ポンド）に達しました。 2倍の459億3,000万米ドル（351億ポンド）となりました。この医療支出の急増は、免疫療法薬市場の成長を大きく促進します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界の免疫療法薬市場の促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の免疫療法薬市場規模実績と成長率、2018～2023年
• 世界の免疫療法薬市場規模と成長予測、2023～2028年、2033年

第6章 市場セグメンテーション

• 世界の免疫療法薬市場、タイプ別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• モノクローナル抗体
• インターフェロン
• インターロイキン
• ワクチン
• チェックポイント阻害剤
• その他
• 世界の免疫療法薬市場、治療分野別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• がん
• 自己免疫疾患と炎症疾患
• 感染症
• その他
• 世界の免疫療法薬市場、エンドユーザー別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• 病院とクリニック
• 外来手術センター
• その他

第7章 地域と国の分析

• 世界の免疫療法薬市場、地域別、実績と予測、2018～2023年、2023～2028年、2033年
• 世界の免疫療法薬市場、国別、実績と予測、2018～2023年、2023～2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 免疫療法薬市場の競合情勢
• 免疫療法薬市場の企業プロファイル
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Amgen Inc.
  • AbbVie Inc.
  • Merck &Co. Inc

第31章 競合ベンチマーキング

第32章 競合ダッシュボード

第33章 主要な合併と買収

第34章 将来の展望と潜在性分析

第35章 付録

Immunotherapy drugs constitute a category of medications designed to modulate the immune system, either by enhancing or suppressing it, to bolster the body's defense against cancer, infections, and various ailments. This approach to cancer treatment harnesses the body's immune response to combat the disease.

The primary classes of immunotherapy drugs encompass monoclonal antibodies, interferons, interleukins, vaccines, checkpoint inhibitors, and other specialized treatments. Monoclonal antibodies, for instance, are produced by replicating a single white blood cell, allowing the lineage of each antibody to be traced back to its originating parent cell. These drugs find application across diverse medical domains such as cancer treatment, autoimmune conditions, inflammatory diseases, and combating infections. They are employed across various healthcare settings including hospitals, clinics, ambulatory surgical centers, and other healthcare facilities.

The drugs for immunotherapy market research report is one of a series of new reports from The Business Research Company that provides drugs for immunotherapy market statistics, including drugs for immunotherapy industry global market size, regional shares, competitors with drugs for immunotherapy market share, detailed drugs for immunotherapy market segments, market trends and opportunities, and any further data you may need to thrive in the drugs for immunotherapy industry. This drug for immunotherapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The drugs for immunotherapy market size has grown rapidly in recent years. It will grow from $255.14 billion in 2023 to $281.43 billion in 2024 at a compound annual growth rate (CAGR) of 10.3%. During the historical period, growth was primarily propelled by factors like the increasing prevalence of cancer, unfulfilled medical requirements, heightened awareness regarding cancer immunotherapy, greater acceptance and utilization of immunotherapeutic methods, as well as increased investments made by major pharmaceutical companies in this field.

The drugs for immunotherapy market size is expected to see rapidly grown in the next few years. It will grow to $445.12 billion in 2028 at a compound annual growth rate (CAGR) of 12.1%. Anticipated growth in the forecast period is expected to stem from the introduction of combination therapies, the rise of personalized medicine, global expansion initiatives, the development of biomarker-driven treatments, and the escalation in clinical trials. Key trends projected for this period encompass progressions in immunology, advancements in CAR-T cell therapies, the emergence of targeted immunotherapies, the exploration of immunotherapy combinations, and the innovation surrounding neoantigen vaccines.

The burgeoning prevalence of cancer worldwide stands as the primary impetus behind the escalating demand for drugs in the immunotherapy market. The proliferation of cancer cases, attributed to factors like obesity, smoking, alcohol consumption, and dietary habits, is projected to soar significantly. Reports from Macmillan Cancer Support in October 2022 estimated a steep rise in cancer cases, predicting 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. With breast, lung, colon, rectum, and prostate cancers ranking as the most widespread types, lifestyle elements such as tobacco use, high BMI, limited fruit and vegetable intake, alcohol consumption, and lack of exercise contribute to roughly one-third of cancer-related deaths. This escalation in cancer incidence is set to drive up the demand for immunotherapy drugs, consequently fueling market growth.

The escalating trajectory of healthcare spending is anticipated to serve as a driving force propelling the growth of the immunotherapy drugs market. Healthcare expenditure encompasses the collective monetary outlay on healthcare services within a specified region or nation over a designated duration, encompassing expenses on medical consultations, hospitalizations, surgical procedures, diagnostics, and treatments. Notably, recent statistics from The Office for National Statistics in May 2023 indicated a substantial surge in healthcare spending within the UK. Figures revealed a nominal increase of 9.4% and a real increase of 9.7%, with total healthcare spending reaching $367.25 billion (£280.7 billion) in 2021. Pharmaceutical spending notably amounted to $51.84 billion (£39.6 billion), while preventive care spending more than doubled to $45.93 billion (£35.1 billion). This upsurge in healthcare expenditure significantly fuels the growth of the immunotherapy drugs market.

Prominent entities within the immunotherapy drugs market are strategically focused on innovating novel products such as Keytruda (pembrolizumab), aimed at delivering dependable services to consumers. Keytruda, an immune checkpoint inhibitor categorized under immunotherapy, was launched by Merck & Co., Inc. in January 2023. Approved by the US Food and Drug Administration, this breakthrough therapy assists the immune system in combating cancer cells, notably approved as an adjuvant treatment for non-small cell lung cancer (NSCLC). This development stands as a substantial leap in cancer treatment, poised to positively impact the healthcare industry's landscape.

Manufacturers of drugs for immunotherapy market are increasingly collaborating or partnering with other companies to share technology, resources, and product knowledge and expand the business. For example, Illumina Inc. and Bristol-Myers Squibb (BMS) collaborated to utilize Illumina's next-generation sequencing (NGS) technology to develop and commercialize in-vitro diagnostic (IVD) assays in support of Bristol-Myers Squibb's oncology portfolio. Allogene Therapeutics Inc. and Pfizer Inc. entered into an asset contribution agreement to use Pfizer's portfolio of assets related to allogeneic CAR-T therapy.

In November 2021, Pfizer Inc., a prominent pharmaceutical company based in the US, completed the acquisition of Trillium Therapeutics for a total of $2.22 billion. Through this strategic acquisition, Pfizer aims to broaden its oncology portfolio by incorporating advanced investigational immuno-therapeutics designed for hematological malignancies. Trillium Therapeutics, a biotechnology company headquartered in Canada, specializes in providing immunotherapy drugs, making this acquisition a significant move for Pfizer to expand its offerings in this therapeutic area.

Major companies operating in the drugs for immunotherapy market include F. Hoffmann-La Roche Ltd., Novartis AG, Amgen Inc., AbbVie Inc., Merck & Co. Inc., GlaxoSmithKline PLC, Eli Lilly and Company, Bristol-Myers Squibb, AstraZeneca PLC, Johnson & Johnson, UbiVac, Pfizer Inc., Sanofi SA, Bayer AG, Celgene Corporation, Incyte Corporation, Juno Therapeutics Inc., Bluebird bio, Celldex Therapeutics, BeiGene, BioNTech AG, CytomX Therapeutics, Eisai Co. Ltd., Flexus Biosciences Inc., Genscript Biotech Corporation, Gilead Sciences Inc., Harpoon Therapeutics Inc., Heptares Therapeutics Ltd., Ignyta Inc., Immatics Biotechnologies, Jounce Therapeutics Inc.

North America was the largest region in the immunotherapy market in 2023. Middle East is expected to be the fastest growing region in the drug for immunotherapy market report during the forecast period. The regions covered in the drugs for immunotherapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the drugs for immunotherapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The drugs for immunotherapy market consist of sales of cytokines, CAR T-cell therapy, and cancer treatment vaccines. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Drugs for Immunotherapy Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on drugs for immunotherapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for drugs for immunotherapy? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The drugs for immunotherapy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Type: Monoclonal Antibodies; Interferons; Interleukins; Vaccines; Checkpoint Inhibitors; Other Types
• 2) By Therapy Area: Cancer; Autoimmune & Inflammatory Diseases; Infectious Diseases; Other Therapy Areas
• 3) By End User: Hospitals & Clinics; Ambulatory Surgical Centers; Other End Users
• Companies Mentioned: F. Hoffmann-La Roche Ltd.; Novartis AG; Amgen Inc.; AbbVie Inc.; Merck & Co. Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Drugs For Immunotherapy Market Characteristics

3. Drugs For Immunotherapy Market Trends And Strategies

4. Drugs For Immunotherapy Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On the Market
• 4.2. Ukraine-Russia War Impact On the Market
• 4.3. COVID-19 Impact On the Market

5. Global Drugs For Immunotherapy Market Size and Growth

• 5.1. Global Drugs For Immunotherapy Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Drugs For Immunotherapy Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Drugs For Immunotherapy Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Drugs For Immunotherapy Market Segmentation

• 6.1. Global Drugs For Immunotherapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Monoclonal Antibodies
• Interferons
• Interleukins
• Vaccines
• Checkpoint Inhibitors
• Other Types
• 6.2. Global Drugs For Immunotherapy Market, Segmentation By Therapy Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Cancer
• Autoimmune And Inflammatory Diseases
• Infectious Diseases
• Other Therapy Areas
• 6.3. Global Drugs For Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospitals And Clinics
• Ambulatory Surgical Centers
• Other End Users

7. Drugs For Immunotherapy Market Regional And Country Analysis

• 7.1. Global Drugs For Immunotherapy Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Drugs For Immunotherapy Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Drugs For Immunotherapy Market

• 8.1. Asia-Pacific Drugs For Immunotherapy Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Drugs For Immunotherapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Drugs For Immunotherapy Market, Segmentation By Therapy Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Drugs For Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Drugs For Immunotherapy Market

• 9.1. China Drugs For Immunotherapy Market Overview
• 9.2. China Drugs For Immunotherapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Drugs For Immunotherapy Market, Segmentation By Therapy Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Drugs For Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Drugs For Immunotherapy Market

• 10.1. India Drugs For Immunotherapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Drugs For Immunotherapy Market, Segmentation By Therapy Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Drugs For Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Drugs For Immunotherapy Market

• 11.1. Japan Drugs For Immunotherapy Market Overview
• 11.2. Japan Drugs For Immunotherapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Drugs For Immunotherapy Market, Segmentation By Therapy Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Drugs For Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Drugs For Immunotherapy Market

• 12.1. Australia Drugs For Immunotherapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Drugs For Immunotherapy Market, Segmentation By Therapy Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Drugs For Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Drugs For Immunotherapy Market

• 13.1. Indonesia Drugs For Immunotherapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Drugs For Immunotherapy Market, Segmentation By Therapy Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Drugs For Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Drugs For Immunotherapy Market

• 14.1. South Korea Drugs For Immunotherapy Market Overview
• 14.2. South Korea Drugs For Immunotherapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Drugs For Immunotherapy Market, Segmentation By Therapy Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Drugs For Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Drugs For Immunotherapy Market

• 15.1. Western Europe Drugs For Immunotherapy Market Overview
• 15.2. Western Europe Drugs For Immunotherapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Drugs For Immunotherapy Market, Segmentation By Therapy Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Drugs For Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Drugs For Immunotherapy Market

• 16.1. UK Drugs For Immunotherapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Drugs For Immunotherapy Market, Segmentation By Therapy Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Drugs For Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Drugs For Immunotherapy Market

• 17.1. Germany Drugs For Immunotherapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Drugs For Immunotherapy Market, Segmentation By Therapy Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Drugs For Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Drugs For Immunotherapy Market

• 18.1. France Drugs For Immunotherapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Drugs For Immunotherapy Market, Segmentation By Therapy Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Drugs For Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Drugs For Immunotherapy Market

• 19.1. Italy Drugs For Immunotherapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Drugs For Immunotherapy Market, Segmentation By Therapy Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Drugs For Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Drugs For Immunotherapy Market

• 20.1. Spain Drugs For Immunotherapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Drugs For Immunotherapy Market, Segmentation By Therapy Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Drugs For Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Drugs For Immunotherapy Market

• 21.1. Eastern Europe Drugs For Immunotherapy Market Overview
• 21.2. Eastern Europe Drugs For Immunotherapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Drugs For Immunotherapy Market, Segmentation By Therapy Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Drugs For Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Drugs For Immunotherapy Market

• 22.1. Russia Drugs For Immunotherapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Drugs For Immunotherapy Market, Segmentation By Therapy Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Drugs For Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Drugs For Immunotherapy Market

• 23.1. North America Drugs For Immunotherapy Market Overview
• 23.2. North America Drugs For Immunotherapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Drugs For Immunotherapy Market, Segmentation By Therapy Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Drugs For Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Drugs For Immunotherapy Market

• 24.1. USA Drugs For Immunotherapy Market Overview
• 24.2. USA Drugs For Immunotherapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Drugs For Immunotherapy Market, Segmentation By Therapy Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Drugs For Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Drugs For Immunotherapy Market

• 25.1. Canada Drugs For Immunotherapy Market Overview
• 25.2. Canada Drugs For Immunotherapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Drugs For Immunotherapy Market, Segmentation By Therapy Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Drugs For Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Drugs For Immunotherapy Market

• 26.1. South America Drugs For Immunotherapy Market Overview
• 26.2. South America Drugs For Immunotherapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Drugs For Immunotherapy Market, Segmentation By Therapy Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Drugs For Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Drugs For Immunotherapy Market

• 27.1. Brazil Drugs For Immunotherapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Drugs For Immunotherapy Market, Segmentation By Therapy Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Drugs For Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Drugs For Immunotherapy Market

• 28.1. Middle East Drugs For Immunotherapy Market Overview
• 28.2. Middle East Drugs For Immunotherapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Drugs For Immunotherapy Market, Segmentation By Therapy Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Drugs For Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Drugs For Immunotherapy Market

• 29.1. Africa Drugs For Immunotherapy Market Overview
• 29.2. Africa Drugs For Immunotherapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Drugs For Immunotherapy Market, Segmentation By Therapy Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Drugs For Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Drugs For Immunotherapy Market Competitive Landscape And Company Profiles

• 30.1. Drugs For Immunotherapy Market Competitive Landscape
• 30.2. Drugs For Immunotherapy Market Company Profiles
  • 30.2.1. F. Hoffmann-La Roche Ltd.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Novartis AG
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Amgen Inc.
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. AbbVie Inc.
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Merck & Co. Inc
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Global Drugs For Immunotherapy Market Competitive Benchmarking

32. Global Drugs For Immunotherapy Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Drugs For Immunotherapy Market

34. Drugs For Immunotherapy Market Future Outlook and Potential Analysis

• 34.1 Drugs For Immunotherapy Market In 2028 - Countries Offering Most New Opportunities
• 34.2 Drugs For Immunotherapy Market In 2028 - Segments Offering Most New Opportunities
• 34.3 Drugs For Immunotherapy Market In 2028 - Growth Strategies
  • 34.3.1 Market Trend Based Strategies
  • 34.3.2 Competitor Strategies

35. Appendix

• 35.1. Abbreviations
• 35.2. Currencies
• 35.3. Historic And Forecast Inflation Rates
• 35.4. Research Inquiries
• 35.5. The Business Research Company
• 35.6. Copyright And Disclaimer